1. Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder (青黄散) in Patients with Myelodysplastic Syndrome
- Author
-
Yong-Gang Xu, Bowen Yi, Xiaoqing Guo, Xiao-Mei Hu, Qian-Zhe Zhu, Zhongyang Deng, Xiao-hong Shang, Hongzhi Wang, Rou Ma, Shirong Zhu, Mingjing Wang, Pan Zhao, and Su Fang
- Subjects
medicine.medical_specialty ,Abdominal pain ,Blood transfusion ,Hemoglobin increased ,medicine.medical_treatment ,Karyotype ,0211 other engineering and technologies ,chemistry.chemical_element ,02 engineering and technology ,030226 pharmacology & pharmacy ,Gastroenterology ,Arsenicals ,Arsenic ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,021105 building & construction ,medicine ,Humans ,Blood Transfusion ,Pharmacology (medical) ,In patient ,business.industry ,General Medicine ,Blood Cell Count ,Diarrhea ,Complementary and alternative medicine ,chemistry ,Myelodysplastic Syndromes ,Digestive tract ,Powders ,medicine.symptom ,business ,After treatment ,Drugs, Chinese Herbal - Abstract
To investigate the relation of blood arsenic concentration (BAC) with clinical effect and safety of arsenic-containing Qinghuang Powder (青黄散, QHP) in patients with myelodysplastic syndrome (MDS). Totally 163 patients with MDS were orally treated with QHP for 2 courses of treatment, 3 months as 1 course. The BACs of patients were detected by atomic fluorescence spectrophotometry at 1, 3, and 6 months during the treatment, and the effective rate, hematological improvement and safety in patients after treatment with QHP were analyzed. After 2 courses of treatment, the total effective rate was 89.6% (146/163), with 31.3% (51/163) of hematological improvement and 58.3% (95/163) of stable disease. The hemoglobin increased from 73.48 ± 19.30 g/L to 80.39 ± 26.56 g/L (P 0.05). Among 46 patients previously depended on blood transfusion, 28.3% (13/46) completely got rid of blood transfusion and 21.7% (10/46) reduced the volume of blood transfusion by more than 50% after treatment. The BACs were significantly increased in patients treated for 1 month with 32.17 ± 18.04 μ g/L (P 0.05). The adverse reactions of digestive tract during the treatment were mild abdominal pain and diarrhea in 14 cases (8.6%), and no patients discontinued the treatment. The BACs of patients with gastrointestinal adverse reactions were significantly lower than those without gastrointestinal adverse reactions (22.39 ± 10.38 vs. 37.89 ± 11.84, μ g/L, P
- Published
- 2019